AFArezoo Faridzadeh

Arezoo Faridzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arezoo Faridzadeh has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Mahmoud Mahmoudi

    Immunology Research Center Mashhad University of Medical Sciences Mashhad Iran

    3 shared publications
  • Zahra Mirfeizi

    Rheumatology Department, Rheumatic Diseases Research Center Mashhad University of Medical Sciences Mashhad Iran

    3 shared publications
  • Amin Tajerian

    School of Medicine Arak University of Medical Sciences Arak Iran

    2 shared publications
  • Farid Poursadegh

    Lung Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    2 shared publications
  • Gisou Erabi

    Student research committee, Urmia University of Medical Sciences, Urmia, Iran

    2 shared publications
  • Maryam Khoshkhui

    Mashhad Univ Med Sci, Dept Allergy & Clin Immunol, Mashhad, Iran

    2 shared publications

Latest Publications

  • Effect of probiotics on allergic rhinitis in children; A systematic review and meta-analysis

    by Aida Bakhshi, Farid Poursadegh, Moeen Salari, Elham Shaarbaf Eidgahi, Safieh Shazdehahmadi, Mahmoud Mahmoudi, Arezoo Faridzadeh

    Background Allergic rhinitis (AR) is a prevalent chronic inflammatory disorder in children, often undiagnosed and associated with reduced quality of life and risk of comorbidities such as asthma. Probiotics have been found to be potential modulators of immune responses in allergic conditions. This systematic review and meta-analysis evaluated the efficacy of probiotics compared with placebo in the management of pediatric AR. Methods Searches were conducted in accordance with a pre-registered protocol using MEDLINE (PubMed), the Web of Science, Scopus, and Embase through April 8, 2025. Randomized controlled trials (RCTs) of children aged < 18 years that compared probiotics, prebiotics, or synbiotics with a placebo were considered for inclusion. Outcomes of interest included clinical and laboratory parameters. Random-effects models with Hedges' g were used; heterogeneity was assessed via I2. Results Fourteen RCTs involving 1,739 children were included. Meta-analysis revealed a significant reduction in nasal symptom scores (SMD = –1.40; 95% CI: –2.26 to –0.54; I2 = 91.3%) and eye symptom scores (SMD = –3.59; 95% CI: –5.84 to –1.33; I2 = 94.3%). Quality of life (RQLQ) was also significantly improved (SMD = –2.98; 95% CI: –4.85 to –1.12; I2 = 95.7%). Among laboratory markers, a small but significant increase in serum eosinophils was observed (SMD = 0.29; 95% CI: 0.06 to 0.52; I2 = 0%). Conclusion: Probiotics were associated with improvements in nasal and ocular symptoms and quality of life in children with AR; however, these findings should be interpreted with caution due to substantial heterogeneity across studies. Probiotics may have a potential role as an adjunctive therapy, but further high-quality, standardized trials are needed. PROSPERO registration code: CRD420250654461 on 24 February 2025. What is Known • Probiotics have been investigated as adjunctive therapy for pediatric allergic rhinitis because of their potential immunomodulatory effects. • Previous studies and meta-analyses have reported inconsistent findings regarding the clinical and immunological effects of probiotics in allergic rhinitis. What is New •This meta-analysis demonstrated significant improvements in nasal symptoms, ocular symptoms, and quality of life in children with allergic rhinitis receiving probiotics versus placebo. • Probiotic supplementation showed no consistent beneficial effects on immunological markers, while substantial heterogeneity remained across studies.

  • Open Access

    Hydatid Cyst of the Right Atrium With Hepatic and Pulmonary Involvement and Concomitant Pulmonary Embolism, Presenting With Massive Haemoptysis: A Case Report

    by Farid Poursadegh, Mahnaz Amini, Javad Ghasemi, Hoorak Poorzand, Hamid Hoseinikhah, Mehdi Farzadnia, Mahnaz Mozdourian, Fariba Rezaeetalab, Arezoo Faridzadeh

    Hydatid cyst disease, caused by Echinococcus granulosus, primarily affects the liver and lungs, while cardiac involvement, especially the right atrium (RA), is extremely rare. We report the case of a 21‐year‐old woman who presented with massive haemoptysis and hypoxemia. Transthoracic echocardiography demonstrated a large multicystic mass occupying the RA cavity, adherent to the atrial wall and interatrial septum, strongly suggestive of a hydatid cyst. Chest computed tomography angiography confirmed multiple pulmonary cystic lesions, intravascular filling defects consistent with pulmonary embolism, and a large hepatic hydatid cyst (5 × 4 cm). Serological testing for echinococcosis was positive. The patient underwent successful surgical excision of the RA cyst and pulmonary embolectomy under cardiopulmonary bypass. This case illustrates the rare presentation of an RA hydatid cyst with multiorgan involvement and associated pulmonary embolism, emphasizing the critical role of comprehensive imaging and timely surgical intervention in the management of complex echinococcosis.

  • Open Access

    The Anti‐Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies

    by Hossein Bahari, Zeinab Salim, Leila Kardanpour, Hosein Kouchaki, Fatemeh Shoja, Iman Rahnama, Arezoo Faridzadeh, Maryam Ranjbar Zahedani

    Chronic myeloid leukemia (CML), a myeloproliferative neoplasm, is characterized by the BCR‐ABL1 fusion gene, which results in constitutive tyrosine kinase activity. While tyrosine kinase inhibitors (TKIs) have significantly improved CML outcomes, resistance and the persistence of leukemic stem cells remain major clinical challenges. Curcumin, a natural polyphenol derived from Curcuma longa , has demonstrated potential anticancer properties. This review explores curcumin's effects on CML cell lines, focusing on its mechanisms of action and therapeutic potential. A systematic literature search was conducted in December 2024 across PubMed, Scopus, and Web of Science databases, following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. The review included original in vitro studies examining curcumin's anti‐leukemic effects on human CML cell lines. Data was extracted and synthesized narratively due to methodological variability. Of 869 screened articles, 21 in vitro studies met the inclusion criteria. Curcumin inhibited proliferation and induced apoptosis in CML cell lines, particularly K562. Key mechanisms included inhibition of protein kinase C alpha (PKCα), Wilms' tumor 1 (WT1), BCR‐ABL1 signaling, and histone deacetylase 8 (HDAC8) expression, as well as modulation of microRNA‐21 (miR‐21), phosphatase and tensin homolog (PTEN), and suppressor of cytokine signaling 1 and 3 (SOCS1/3) pathways. Curcumin also triggered cell cycle arrest at the G2/M phase and promoted autophagy and mitochondrial dysfunction. Notably, curcumin derivatives such as pentagamavunon‐1 (PGV‐1) and compound 1206 (C1206) displayed enhanced potency and overcame resistance in imatinib‐resistant CML cells. Curcumin demonstrates multi‐targeted anti‐leukemic activity in vitro, disrupting oncogenic signaling, epigenetic regulation, and redox balance in CML cells. Its ability to sensitize resistant cells and enhance apoptotic pathways positions it as a promising adjunct to current CML therapies. However, clinical translation requires further investigation to overcome pharmacokinetic limitations and validate efficacy in vivo.


  • Open Access

    Probiotic Interventions in Systemic Sclerosis Patients: A Systematic Review and Future Prospects

    by Zahra Mirfeizi, Mahmoud Mahmoudi, Marzieh Monemi, Amin Tajerian, Arezoo Faridzadeh

    Background and Aims: Systemic sclerosis (SSc) is an uncommon autoimmune connective tissue disease distinguished by fibrosis and vascular abnormalities, often leading to gastrointestinal problems. This review explores the potential of probiotics in managing SSc‐related gastrointestinal issues and modulating immune responses, highlighting the need for innovative treatments to improve patient well‐being.Methods: We performed an extensive literature search up to October 2023 in databases, including Web of Science, PubMed/MEDLINE, and Scopus.Result: This review detected four articles that investigated the impact of probiotics on SSc. These studies, comprising non‐randomized observational studies and randomized clinical trials, provide preliminary insights suggesting that probiotics may be efficacious in modulating the immune response and, consequently, in improving gastrointestinal symptoms in SSc patients.Conclusion: The comprehensive review suggests that probiotics may aid in managing gastrointestinal symptoms and modulating immune responses in SSc. However, it is essential to acknowledge the limited existing evidence, underscoring the need for more rigorous randomized controlled trials to thoroughly assess their effectiveness.


  • Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis

    by Amin Tajerian, Ali Pourvali, Maryam Khoshkhui, Mehraneh Movahedi Aliabadi, Mahya Mobinikhaledi, Arezoo Faridzadeh

    Chronic urticaria is a persistent skin condition characterized by recurrent wheals (hives) and/or angioedema lasting more than six weeks, significantly impacting quality of life and often requiring long-term management. Limited access to costly treatments like omalizumab poses challenges in low-income countries with high healthcare expenses and limited insurance coverage, prompting research into cost-effective dosages for effective management. This study aims to find the most cost-effective dosage for treating chronic urticaria in countries with healthcare affordability challenges. PubMed, MEDLINE, and Web of Science databases were searched for randomized controlled trials (RCTs) from January 1, 2010, to October 29, 2023. Studies assessing Omalizumab's efficacy in chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines were included. Network meta-analyses (NMAs) were conducted using the "multinma" package in R, employing Bayesian random-effects models to synthesize data from multiple studies. Each outcome underwent separate analysis, with effect sizes illustrated via forest plots generated using Plotly in R. Individual studies' risk of bias was assessed using the Cochrane Risk of Bias Tool 2, and effect estimate certainty was rated via the GRADE approach. Consistency assumption was evaluated using the unrelated mean effects (UME) model, focusing on each data point's contribution to model fit. Present study showed that the 300 mg dose outperformed others and placebo in reducing urticaria activity score over 7 days (UAS7), weekly itch severity score (WWS), and weekly number of hives score (WIS). Response rates were notably higher with 300 mg, indicating its superiority in achieving treatment response. Given the significantly greater effect sizes of 150 mg and 300 mg over 75 mg and placebo, low doses aren't recommended for antihistamine-resistant cases. Initiating treatment with either a 300 mg dose for six months or starting with 150 mg and adjusting upwards as necessary is recommended, aligning with economic considerations until optimal dosages are established.

  • Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial

    by Zahra Mirfeizi, Mahmoud Mahmoudi, Mohammad Hassan Jokar, Maryam Sahebari, Elmira Noori, Hasan Mehrad‐Majd, Mehdi Barati, Arezoo Faridzadeh

    Systemic lupus erythematosus (SLE) is an autoimmune disease that affects various organs in the body. In SLE, inflammatory cytokines play a crucial role in initiating and sustaining the inflammatory process. Synbiotics may help modulate these inflammatory cytokines. This randomized, double‐blind, placebo‐controlled clinical trial aimed to assess the impact of synbiotics intervention on interleukin‐17A (IL‐17A) levels, disease activity, and inflammatory factors in patients with SLE. Fifty SLE patients were randomly assigned to receive either standard therapy plus synbiotics (consisting of Streptococcus thermophilus , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus rhamnosus , Lactobacillus salivarius , Lactobacillus reuteri , Bifidobacterium lactis , Bifidobacterium longum , Bifidobacterium bifidum , and the prebiotic fructooligosaccharides) or standard therapy alone for 2 months. The results demonstrated a significant reduction in both protein and mRNA levels of IL‐17A, as well as in the Systemic Lupus Erythematosus Disease Activity Index 2000 score, within the synbiotics group after the intervention compared to baseline. In contrast, the placebo group did not experience significant changes in IL‐17A levels or disease activity. Synbiotic supplementation shows potential as an adjunctive therapeutic approach for SLE management; however, further research is needed to elucidate its underlying mechanisms. Practical Application: This study explores the use of synbiotics as a supplementary treatment for systemic lupus erythematosus, which is typically managed with immunosuppressive therapies.


  • Natural STAT3 Inhibitors for Cancer Treatment: A Comprehensive Literature Review

    by Seyed Mahdi Zarezadeh, Amir Mohammad Sharafi, Gisou Erabi, Arefeh Tabashiri, Navid Teymouri, Hoda Mehrabi, Seyyed Amirhossein Golzan, Arezoo Faridzadeh, Zahra Abdollahifar, Nafiseh Sami, et al.

    Cancer is one of the leading causes of mortality and morbidity worldwide, affecting millions of people physically and financially every year. Over time, many anticancer treatments have been proposed and studied, including synthetic compound consumption, surgical procedures, or grueling chemotherapy. Although these treatments have improved the daily life quality of patients and increased their survival rate and life expectancy, they have also shown significant drawbacks, including staggering costs, multiple side effects, and difficulty in compliance and adherence to treatment. Therefore, natural compounds have been considered a possible key to overcoming these problems in recent years, and thorough research has been done to assess their effectiveness. In these studies, scientists have discovered a meaningful interaction between several natural materials and signal transducer and activator of transcription 3 molecules. STAT3 is a transcriptional protein that is vital for cell growth and survival. Mechanistic studies have established that activated STAT3 can increase cancer cell proliferation and invasion while reducing anticancer immunity. Thus, inhibiting STAT3 signaling by natural compounds has become one of the favorite research topics and an attractive target for developing novel cancer treatments. In the present article, we intend to comprehensively review the latest knowledge about the effects of various organic compounds on inhibiting the STAT3 signaling pathway to cure different cancer diseases.


  • Open Access

    Potential applications of macrophages in cancer immunotherapy

    by Maryam Sadri, Sahel Heidari, Arezoo Faridzadeh, Mona Roozbehani, Shirin Toosi, Reihaneh Alsadat Mahmoudian, Akram Hoseinzadeh, Mohammad Taha Salmani Fard, Fahimeh Lavi Arab, Soheil Rahmani Fard, et al.


  • Open Access

    SARS‐CoV‐2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID‐19 pandemic

    by Gisou Erabi, Arezoo Faridzadeh, Ali Parvin, Niloofar Deravi, Mohammad Rahmanian, Mobina Fathi, Elahe Aleebrahim‐Dehkordi, Nima Rezaei

    Background and Aim: In late 2021, the world faced the rapid spread of the SARS‐CoV‐2 Omicron variant, which quickly became the variant of concern. In April 2022, two new lineages of Omicron (BA.4/BA.5) emerged from Africa, where they caused the fifth wave of infection. Method: We searched PubMed, Google Scholar, and Scopus online databases up to December 2023 for founding relevant studies. Results: BA.4 and BA.5 subgroups, with changes in the spike protein, have a greater ability to escape from the immune system, which was possible with the help of L452R and F486V mutations. Epidemiologically, these evolving subtypes show similarities to seasonal influenza but with higher mortality rates. The symptoms of these subgroups are different from the previous types in the form of upper respiratory symptoms. Antiviral treatments, the use of antibodies such as bebtelovimab, and the development of vaccines are promising. Conclusion: Consequently, we must continue to be vigilant in our joint surveillance efforts against COVID‐19 in diagnosis and treatment.


  • Open Access

    Probiotics as a complementary treatment in systemic lupus erythematosus: A systematic review

    by Zahra Mirfeizi, Mahmoud Mahmoudi, Arezoo Faridzadeh

    Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects young women. SLE has no recognized etiology but it is believed to be triggered by a number of factors, including genetic predisposition, hormonal influences, and environmental conditions. Dysbiosis in the gut microbiota has emerged as a potential mechanism connecting the intestinal microbiome to the breakdown of self‐tolerance and chronic inflammation. This review aims to investigate the role of probiotics in modulating the gut microbiome and their potential therapeutic benefits in managing SLE, providing insights for future research and clinical practice.Methods: We conducted a thorough search for papers published up to June 2023 in databases such as PubMed/MEDLINE, Web of Science, Scopus, and Cochrane Library.Results: The systematic review identified 22 articles examining the effects of probiotics on SLE. These studies—which include in vivo tests, in vitro research, and clinical trials—indicate that probiotics may be effective against inflammation, and improve immunological responses and metabolic profiles in SLE patients. Most in vivo studies were assessed as medium to high quality, while the randomized controlled trial was deemed of high quality.Conclusion: According to the findings of our systematic review, probiotics may be used in conjunction with other treatments to manage SLE. Nonetheless, current data is limited, and more randomized controlled trials would be required to fully examine their effectiveness.